Case Reports in Critical Care (Jan 2023)

Type B Lactic Acidosis in a Patient with Mantle Cell Lymphoma

  • Ikemsinachi C. Nzenwa,
  • Margaret Berquist,
  • Toby J. Brenner,
  • Aida Ansari,
  • Hamid D. Al-Fadhl,
  • Michael Aboukhaled,
  • Shivani S. Patel,
  • Ethan E. Peck,
  • Mahmoud D. Al-Fadhl,
  • Anthony V. Thomas,
  • Nuha Zackariya,
  • Mark M. Walsh,
  • Jose A. Bufill

DOI
https://doi.org/10.1155/2023/7021123
Journal volume & issue
Vol. 2023

Abstract

Read online

Type B lactic acidosis is an uncommon medical emergency in which acid production overwhelms hepatic clearance. This specific etiology of lactic acidosis occurs without organ hypoperfusion and has been most commonly described in patients with hematologic malignancies but also in patients with solid tumors. The mechanism by which cancer cells switch their glucose metabolism toward increasingly anaerobic glycolytic phenotypes has been described as the “Warburg effect.” Without treating the underlying malignancy, the prognosis for patients diagnosed with malignancy-related type B lactic acidosis is extremely poor. Here, we present a case of a 66-year-old male who was diagnosed with type B lactic acidosis secondary to mantle cell lymphoma. Bicarbonate drip was started to correct the lactic acidosis. The patient was also immediately treated with rituximab chemotherapy combined with rasburicase to avoid the hyperuricemia associated with tumor lysis syndrome. He responded to the early treatment and was discharged with normal renal function. Type B lactic acidosis secondary to hematologic malignancy is important to recognize. In order to successfully treat this syndrome, early diagnosis and simultaneous treatment of the imbalance of lactic acid levels and the underlying malignancy are necessary.